ArticleNeural regeneration research2026
Regulatory T cells in stroke inflammation: Therapeutic perspectives.
Article in Neural regeneration research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Akkermansia muciniphila : A next-generation gut probiotic supporting neurorepair and functional recovery.Neural regeneration research · 2026Article
- The gut virome and regulatory T cell axis in health and systemic disease.Microbiome research reports · 2026Review
- Treg cells protect astrocytes from ferroptosis after subarachnoid hemorrhage by activating the HIF-1α/Hmox1 pathway.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory T cells are crucial immunomodulatory cells that play essential roles in both ischemic stroke and intracerebral hemorrhage. These cells are vital in post-stroke inflammation since they suppress immune responses and promote tissue repair. This review thoroughly examines the dynamic changes in the number and function of regulatory T cells and highlights their distinct roles at various stages of stroke progression. In the acute phase (within 5-7 days), regulatory T cells exert neuroprotective effects primarily by reducing inflammation. In the chronic phase (7 days post-onset), these cells support neuroregeneration and functional recovery. The review also explores the emerging role of regulatory T cells in the brain-gut axis, a key mediator of the systemic immune responses following stroke, and discusses its relevance in modulating post-stroke inflammation and repair. Various strategies aimed at enhancing regulatory T cell responses include adoptive transfer of regulatory T cells, administration of pharmacological agents, and induction of mucosal tolerance. All these approaches can potentially enhance the immunomodulatory and repair functions of regulatory T cells. Nevertheless, despite the promising preclinical results, the translation of regulatory T cell-based therapies into clinical practice is associated with challenges related to optimal timing, dosage, and long-term efficacy. Overall, targeting regulatory T cells is a novel and promising immunoregulatory approach for mitigating stroke-induced injury and promoting neural repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.